Jack supports clients with evidence-based research and analysis that spans healthcare sectors and stakeholders.

With a background in health economics, statistical analysis, and health policy, he contributes to the development of client analysis and insights.

Jack’s background in health policy and health economics includes varied research experiences. As a Congressional intern, he attended and transcribed financial services and healthcare policy hearings to support the development of legislative agendas. At the National Community Pharmacy Association, he performed economic research on nationwide drug pricing trends and analyzed the impact of health policy and associated data for impacts to pharmaceutical stakeholders at the regional and state levels. Additionally, at First Horizon National Corporation, he assisted in a wide range of compliance and due-diligence projects within the department of mergers and acquisitions.

Jack has a BS in economics from the George Washington University.

Authored Content


Globally, the need to flatten the epidemic curve of COVID-19 cases has become the top public health priority to save lives and minimize the burden on the health care system. In the absence of treatments and prophylactics for the novel coronavirus, social distancing and quarantine strategies continue to be implemented in the US.

As the Coronavirus Disease 2019 (COVID-19), caused by the novel SARS-CoV-2 virus, rapidly spreads through the US, media and public scrutiny over the current diagnostic testing landscape has increased, given that the US lags behind other countries in the number of tests performed and turnaround time for results reported.